DM
ADVM

Deerfield Management’s Adverum Biotechnologies ADVM Stock Holding History

Deerfield Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-282,700
Closed -$9.89M – 134
2021
Q2 		$9.89M Buy
282,700
+42,256
+18% +$2.28M 0.18% 116
2021
Q1 		$23.7M Hold
240,444
– – 0.5% 68
2020
Q4 		$26.1M Hold
240,444
– – 0.52% 63
2020
Q3 		$24.8M Buy
240,444
+157,054
+188% +$23.5M 0.6% 56
2020
Q2 		$17.4M Sell
83,390
-124,110
-60% -$22M 0.51% 64
2020
Q1 		$20.3M Buy
207,500
+186,366
+882% +$21.7M 0.64% 49
2019
Q4 		$2.44M Buy
+21,134
New +$1.86M 0.08% 72
2018
Q2 		– Sell
-42,200
Closed -$2.45M – 115
2018
Q1 		$2.45M Buy
+42,200
New +$2.63M 0.08% 109
2015
Q2 		– Sell
-211,747
Closed -$85.8M – 125
2015
Q1 		$85.8M Buy
211,747
+50,280
+31% +$21.3M 2.78% 7
2014
Q4 		$87.2M Sell
161,467
-43,301
-21% -$16.7M 3.13% 6
2014
Q3 		$70M Buy
+204,768
New +$60.9M 2.55% 6

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management's ADVM Position: Q3 2021 in Review

Deerfield Management sold out of Adverum Biotechnologies (ADVM) in Q3 2021, closing a stake of 282,700 shares — an estimated $9.89M sold.

Deerfield Management first reported a position in ADVM in Q3 2014 and held it in 11 quarters. The position peaked at $87.2M in Q4 2014. 110 funds tracked by Wall St. Rank hold ADVM as of Q3 2021.

  • Deerfield Management reported no remaining Adverum Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Deerfield Management sold 282,700 Adverum Biotechnologies shares in Q3 2021, an estimated $9.89M.
  • Deerfield Management first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 11 quarters.
  • Deerfield Management's Adverum Biotechnologies position peaked at $87.2M in Q4 2014.
  • 110 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2021.

Based on Deerfield Management's 13F filing for Q3 2021, filed 15 Nov 2021.